Budipramana, Krisyanti and Sangande, Frangky (2024) Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy. Chemical Biology and drug design, 103 (5). e14534/1-15. ISSN 1747-0277; E-ISSN 1747-0285
![]() |
PDF
Structural and molecular insights.pdf Restricted to Repository staff only Download (6MB) | Request a copy |
Abstract
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor 2 (VEGFR2) are known as valid targets for cancer therapy. Overexpression of EGFR induces uncontrolled cell proliferation and VEGF expression triggering angiogenesis via VEGFR2 signaling. On the other hand, VEGF expression independent of EGFR signaling is already known as one of the mechanisms of resistance to anti-EGFR therapy. Therefore, drugs that act as dual inhibitors of EGFR and VEGFR2 can be a solution to the problem of drug resistance and increase the effectiveness of therapy. In this review, we summarize the relationship between EGFR and VEGFR2 signal transduction in promoting cancer growth and how their kinase domain structures can affect the selectivity of an inhibitor as the basis for designing dual inhibitors. In addition, several recent studies on the development of dual EGFR and VEGFR2 inhibitors involving docking simulations were highlighted in this paper to provide some references such as pharmacophore features of inhibitors and key residues for further research, especially in computer-aided drug design.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | cancer, dual inhibitor, EGFR, pharmacophore, VEGFR2 |
Subjects: | R Medicine > RS Pharmacy and materia medica |
Divisions: | Faculty of Pharmacy > Department of Pharmacy |
Depositing User: | KRISYANTI BUDIPRAMANA |
Date Deposited: | 06 May 2024 01:19 |
Last Modified: | 06 May 2024 02:06 |
URI: | http://repository.ubaya.ac.id/id/eprint/46315 |
Actions (login required)
![]() |
View Item |